David Weill - 27 Feb 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Director
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Issuer symbol
TMDX
Transactions as of
27 Feb 2023
Transactions value $
-$370,837
Form type
4
Filing time
28 Feb 2023, 16:01:32 UTC
Previous filing
14 Nov 2022
Next filing
30 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $84.3K +5.93K +59.34% $14.20 15.9K 27 Feb 2023 Direct
transaction TMDX Common Stock Sale -$74.8K -964 -6.05% $77.64 15K 27 Feb 2023 Direct F1
transaction TMDX Common Stock Sale -$380K -4.97K -33.2% $76.51 10K 27 Feb 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -5.93K -37.24% $0.00 10K 27 Feb 2023 Common Stock 5.93K $14.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $77.63 to $77.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $76.44 to $76.65, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 A Form 4 filed by the reporting person on November 14, 2022 inadvertently overstated the total number of shares held by the reporting person by 3,500 shares. The updated amounts reported here correct that error and reflect the reporting person's holdings.
F4 The option is fully vested.